Pfizer and Ipsen-backed Rhythm Pharmaceuticals has filed for an initial public offering on Nasdaq.
Rhythm Pharmaceuticals, a US-based peptide therapeutics developer backed by pharmaceutical firms Pfizer and Ipsen, filed for a $115m initial public offering on Nasdaq on Tuesday.
Founded in 2008, Rhythm is working on treatments for rare genetic disorders such as pro-opiomelanocortin (POMC) deficiency obesity and Prader-Willi syndrome, which cause patients to have insatiable hunger and lead to massive gain weights from an early age.
The company has raised $114m in funding, most recently securing $41m in a February 2017 round…
